HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.
Company Details
- Employees
- 27
- Address
- 619 West 54th Street,
- Phone
- 212-601-2800
- co****@****ell.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- hibercell.com
- HQ
- New York, New York
Hibercell Questions
Hibercell's helpline number is 212-601-2800
Hibercell's website is hibercell.com
Hibercell's LinkedIn profile is https://www.linkedin.com/company/hibercell
Hibercell has
27 employees.
View email and phone details for 27
employees at Hibercell.
Hibercell's industry is
Biotechnology Research
Hibercell's top competitors are
Genseq,
Cellarity,
Caption Health,
Volastra Therapeutics,
Nuritas,
Epitopea,
Pathos,
Kriya Therapeutics, Inc.,
Genuity Science,
Moma Therapeutics.
Hibercell's support email address is contact@hibercell.com
Hibercell's categories are Biotechnology Research
